Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about RAN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
RAN is a gene implicated in neurodegeneration research. Key relationships include: associated with, therapeutic target, activates. Associated with Aging, Als, Amyotrophic Lateral Sclerosis. Connected to 73 entities in the SciDEX knowledge graph.
No AI portrait yet
| Gene Symbol | RAN |
| Chromosome | 12q24.1 |
| Amino Acids | 216 aa |
| Exons | 8 |
| Pathways | Epigenetic, Notch, Circadian Rhythm, Tumor Microenvironment, Lipid Metabolism |
| GeneCards | RAN |
| Human Protein Atlas | RAN |
| 2019 | Partnership with Anthem (now Elevance Health) to deploy AI platform[@anthem] |
| 2020 | Launch of virtual care services in response to COVID-19 pandemic |
| 2021 | Acquisition of Hydrogen Health and Livongo assets |
| 2022 | Workforce reduction of approximately 30% |
| 2023 | Transition to profitability focus |
| 2024 | Continued expansion of primary care services |
| Associated Diseases | Aging, Als, Amyotrophic Lateral Sclerosis, Ataxia, Dementia, frontotemporal dementia |
| Known Drugs/Compounds | metformin, rapamycin |
| Interactions | Actin, Akt, AKT, ALS, AMPK, AMYOTROPHIC LATERAL SCLEROSIS |
| KG Connections | 155 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
RAN["RAN"]
Als{"Als"}
RAN -->|"associated with"| Als
Ms{"Ms"}
RAN -->|"interacts with"| Ms
Amyotrophic_Lateral_Sclerosis{"Amyotrophic Lateral Sclerosis"}
RAN -->|"interacts with"| Amyotrophic_Lateral_Sclerosis
Dementia{"Dementia"}
RAN -->|"associated with"| Dementia
Ataxia{"Ataxia"}
RAN -->|"associated with"| Ataxia
Huntington{"Huntington"}
RAN -->|"associated with"| Huntington
RAN -->|"associated with"| Ms
RAN -->|"associated with"| Amyotrophic_Lateral_Sclerosis
Inflammation{"Inflammation"}
RAN -->|"inhibits"| Inflammation
RAN -->|"regulates"| Als
Neuroinflammation{"Neuroinflammation"}
RAN -->|"inhibits"| Neuroinflammation
RAN -->|"inhibits"| Amyotrophic_Lateral_Sclerosis
C9ORF72["C9ORF72"]
C9ORF72 -->|"interacts with"| RAN
C9ORF72 -->|"associated with"| RAN
P62["P62"]
P62 -->|"inhibits"| RAN
NOTCH3["NOTCH3"]
NOTCH3 -->|"associated with"| RAN
EIF2A["EIF2A"]
EIF2A -->|"inhibits"| RAN
NEURODEGENERATIVE_DISEASES["NEURODEGENERATIVE DISEASES"]
NEURODEGENERATIVE_DISEASES -->|"associated with"| RAN
EIF2A -->|"activates"| RAN
ATG["ATG"]
ATG -->|"associated with"| RAN
FTLD["FTLD"]
FTLD -->|"contributes to"| RAN
NEURODEGENERATIVE_DISORDERS["NEURODEGENERATIVE DISORDERS"]
NEURODEGENERATIVE_DISORDERS -->|"associated with"| RAN
style RAN fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| Amyotrophic Lateral Sclerosis | associated_with | disease | 0.75 |
| Als | associated_with | disease | 0.75 |
| ATG | associated_with | gene | 0.70 |
| AMYOTROPHIC LATERAL SCLEROSIS | associated_with | gene | 0.70 |
| RNA | regulates | gene | 0.70 |
| Hepatocellular Carcinoma | activates | disease | 0.65 |
| Als | activates | disease | 0.65 |
| Tumor | regulates | disease | 0.65 |
| Cancer | interacts_with | disease | 0.65 |
| Ms | inhibits | disease | 0.65 |
| Tumor | activates | disease | 0.65 |
| Aging | associated_with | disease | 0.65 |
| Carcinoma | activates | disease | 0.65 |
| Frontotemporal Dementia | expressed_in | disease | 0.65 |
| Neurodegeneration | associated_with | disease | 0.65 |
| Amyotrophic Lateral Sclerosis | expressed_in | disease | 0.65 |
| Dementia | expressed_in | disease | 0.65 |
| Tauopathy | associated_with | disease | 0.65 |
| Dementia | inhibits | disease | 0.65 |
| Dementia | associated_with | disease | 0.65 |
| Ataxia | associated_with | disease | 0.65 |
| Huntington | associated_with | disease | 0.65 |
| Inflammation | inhibits | disease | 0.65 |
| Ms | associated_with | disease | 0.65 |
| Als | therapeutic_target | disease | 0.65 |
| Neuroinflammation | inhibits | disease | 0.65 |
| Inflammation | therapeutic_target | disease | 0.65 |
| Als | regulates | disease | 0.65 |
| Ms | interacts_with | disease | 0.65 |
| Amyotrophic Lateral Sclerosis | interacts_with | disease | 0.65 |
| Amyotrophic Lateral Sclerosis | inhibits | disease | 0.65 |
| AMYOTROPHIC LATERAL SCLEROSIS | inhibits | gene | 0.60 |
| NEUROTOXICITY | associated_with | gene | 0.60 |
| NEUROINFLAMMATION | inhibits | gene | 0.60 |
| ALS | regulates | gene | 0.60 |
| DEMENTIA | associated_with | gene | 0.60 |
| HUNTINGTON | associated_with | gene | 0.60 |
| HUNTINGTON'S DISEASE | associated_with | gene | 0.60 |
| ALS | therapeutic_target | gene | 0.60 |
| Blood-Brain Barrier | interacts_with | pathway | 0.60 |
| Cholesterol | therapeutic_target | pathway | 0.60 |
| Erk | activates | protein | 0.60 |
| Actin | interacts_with | protein | 0.60 |
| RNA | activates | gene | 0.60 |
| Akt | activates | protein | 0.60 |
| oxidative stress response | participates_in | pathway | 0.60 |
| DMPK | associated_with | gene | 0.60 |
| TAU | associated_with | gene | 0.60 |
| C9ORF72 | associated_with | gene | 0.60 |
| RB1 | activates | gene | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| C9ORF72 | associated_with | gene | 0.70 |
| ATG | associated_with | gene | 0.70 |
| LC3 | activates | gene | 0.60 |
| C9ORF72 | therapeutic_target | gene | 0.60 |
| CNBP | associated_with | gene | 0.60 |
| DDX3X | regulates | gene | 0.60 |
| NEURODEGENERATIVE DISEASES | associated_with | gene | 0.60 |
| NEURODEGENERATION | associated_with | gene | 0.60 |
| GENES | associated_with | gene | 0.60 |
| AMYOTROPHIC LATERAL SCLEROSIS | associated_with | gene | 0.60 |
| DEMENTIA | expressed_in | gene | 0.60 |
| REPEAT-CONTAINING TRANSCRIPTS | associated_with | gene | 0.60 |
| AMYOTROPHIC LATERAL SCLEROSIS | expressed_in | gene | 0.60 |
| RNA | expressed_in | gene | 0.60 |
| RNA | interacts_with | gene | 0.60 |
| FAS | activates | gene | 0.60 |
| ERK | activates | gene | 0.60 |
| ATG | regulates | gene | 0.60 |
| PKR | regulates | gene | 0.60 |
| GAIN | associated_with | gene | 0.60 |
| DMPK | associated_with | gene | 0.60 |
| TAU | associated_with | gene | 0.60 |
| ALS | associated_with | gene | 0.60 |
| metformin | targets | drug | 0.60 |
| FIP200 | activates | gene | 0.60 |
| ATXN1 | expressed_in | gene | 0.60 |
| RUNX2 | therapeutic_target | gene | 0.60 |
| CYTOKINES | therapeutic_target | gene | 0.60 |
| IL-6 | therapeutic_target | gene | 0.60 |
| INFLAMMATION | therapeutic_target | gene | 0.60 |
| GENES | therapeutic_target | gene | 0.60 |
| TDP43 | activates | gene | 0.60 |
| AKT | activates | gene | 0.60 |
| FTLD | contributes_to | gene | 0.60 |
| NEURODEGENERATIVE DISORDERS | associated_with | gene | 0.60 |
| TAUOPATHY | associated_with | gene | 0.60 |
| ZNF9/CNBP | associated_with | gene | 0.60 |
| RNA | associated_with | gene | 0.60 |
| AMPK | activates | gene | 0.60 |
| ATG | activates | gene | 0.60 |
| MAP1LC3 | activates | gene | 0.60 |
| MTORC1 | activates | gene | 0.60 |
| rapamycin | targets | drug | 0.60 |
| DNA | activates | gene | 0.60 |
| C9ORF72 | interacts_with | gene | 0.60 |
| P62 | inhibits | gene | 0.60 |
| NOTCH3 | associated_with | gene | 0.60 |
| EIF2A | inhibits | gene | 0.60 |
| EIF2A | activates | gene | 0.60 |
| VEGF | therapeutic_target | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Plant-based dietary patterns and Alzheimer's disease risk in multiethn | clinical | Alzheimer's disease and relate | 0.950 | 0.00 | human patients | proposed | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | in_progress | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
| Autophagy Enhancement Drug Screening for Neurodegeneration | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Macroautophagy Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Validate Mitochondria-Lysosome Contact Site Dysfunction in PD | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic Target Val | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| MLCS Quantification in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Presymptomatic GRN Carrier Intervention Timing — Biomarker-Guided Ther | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeu | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $2,730,000 |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.200 | 0.00 | Mouse (5xFAD/TREM2-/-) | in_progress | N/A |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Hepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammati [PMID:37678798] | Pan Q, Gao M, Kim D, Ai W, Yang W, Jiang | Cell Mol Gastroenterol Hepatol | 2024 | 1 |
| Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] | Zhang T, Xu D, Trefts E, Lv M, Inuzuka H | Science | 2023 | 1 |
| Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Ca [PMID:35642214] | Wang M, Pan W, Xu Y, Zhang J, Wan J, Jia | J Inflamm Res | 2022 | 1 |
| Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and inv [PMID:35176466] | Zhang L, Liang B, Xu H, Gong Y, Hu W, Ji | J Ethnopharmacol | 2022 | 1 |
| TREM2, microglia, and Alzheimer's disease. [PMID:33516818] | Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang | Mech Ageing Dev | 2021 | 1 |
| Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2- [PMID:31932797] | Zhou Y, Song WM, Andhey PS, Swain A, Lev | Nat Med | 2020 | 1 |
| Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK [PMID:31693892] | Wang Y, An H, Liu T, Qin C, Sesaki H, Gu | Cell Rep | 2019 | 1 |
| AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking Sy [PMID:30057310] | Song X, Zhu S, Chen P, Hou W, Wen Q, Liu | Curr Biol | 2018 | 1 |
| TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. [PMID:28802038] | Ulland TK, Song WM, Huang SC, Ulrich JD, | Cell | 2017 | 1 |
| The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Mic [PMID:28930663] | Krasemann S, Madore C, Cialic R, Baufeld | Immunity | 2017 | 1 |
| Obestatin controls the ubiquitin-proteasome and autophagy-lysosome systems in gl [PMID:28675664] | Cid-Díaz T, Santos-Zas I, González-Sánch | J Cachexia Sarcopenia Muscle | 2017 | 1 |
| Precision Neurodegeneration: Integrating Molecular Mechanisms, Biomarkers, and T [PMID:41833042] | ["Lyu G", "Li D"] | CNS & neurological disorders d | 2026 | 0 |
| Emerging pathological mechanisms of Alzheimer's disease pathogenesis: from neuro [PMID:41858793] | ["Wang R", "Feng Y", "Zhou Z", "Jiang J" | Frontiers in aging neuroscienc | 2026 | 0 |
| Human CSF proteogenomics links genetic variation to neurodegenerative disease pr [PMID:41757182] | ["Puerta R", "Garc\u00eda-Gonz\u00e1lez | medRxiv : the preprint server | 2026 | 0 |
| PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tum [PMID:41920736] | Wang Z, Jin N, Li X, Ma X, Feng Y, Yin K | Cell reports | 2026 | 0 |
| Mammalian lipophagy: process and function. [PMID:41681129] | Zhao R, Dai E, Kang R, Liu J, Klionsky D | Autophagy | 2026 | 0 |
| TAZ alleviates ischemic stroke injury by activating Foxo1: Usp1-mediated deubiqu [PMID:41921828] | ["Xin Y", "Sun Y", "Pan E", "Li M", "Che | Free radical biology & medicin | 2026 | 0 |
| PLCG2 signaling and genetic resilience in Alzheimer's disease. [PMID:41888907] | Tsai AP, Martin AK, Mi A, Yeh AE, Ramire | Molecular neurodegeneration | 2026 | 0 |
| Combining network pharmacology and multi-omics reveals the role of Shengdihuang- [PMID:41655545] | Cao X, Shang Y, Qu M, Kang Q, Xu Y et al | Phytomedicine | 2026 | 0 |
| Comparative transcriptomics of adherent and suspension chicken fibroblast cell l [PMID:41763754] | Contreras EJ, Nagarajan A, Bromberg BH, | Food Res Int | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning RAN in their description or question text
Score: 0.912 · Alzheimer's disease · 2026-04-12
## Mechanistic Overview Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via cholec
Score: 0.898 · neurodegeneration · 2026-04-16
## Mechanistic Overview CSF1R Inhibition-Mediated Microglial Replacement as a State Transition Reset starts from the cla
Score: 0.896 · Alzheimer's disease · 2026-04-05
## Mechanistic Overview Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and restore perforant
Score: 0.887 · neurodegeneration · 2026-04-14
## Mechanistic Overview H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from Synapse Pruning to Amyloid Clearance
Score: 0.882 · neurodegeneration · 2026-04-02
## Mechanistic Overview Transcriptional Autophagy-Lysosome Coupling starts from the claim that modulating FOXO1 within t
Score: 0.879 · neurodegeneration · 2026-04-16
## Mechanistic Overview Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State
Score: 0.869 · neuroscience · 2026-04-12
## Mechanistic Overview GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance starts from the claim that m
Score: 0.858 · Alzheimer's disease · 2026-04-05
## Mechanistic Overview Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via direct
Score: 0.858 · neurodegeneration · 2026-04-16
## Mechanistic Overview TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Transition
Score: 0.857 · Alzheimer's disease · 2026-04-05
## Mechanistic Overview Closed-loop tACS targeting EC-II PV interneurons to suppress burst firing and block tau propagat
Score: 0.843 · neurodegeneration · 2026-04-16
## Mechanistic Overview miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Microglia
Score: 0.834 · neurodegeneration · 2026-04-22
## Mechanistic Overview H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State starts from the claim that
Score: 0.827 · Alzheimer's disease · 2026-04-16
## Mechanistic Overview Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymph
Score: 0.827 · Alzheimer's disease · 2026-04-07
## Mechanistic Overview Real-time gamma-guided transcranial focused ultrasound targeting EC-II SST interneurons to resto
Score: 0.827 · Alzheimer's disease · 2026-04-05
## Mechanistic Overview Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling for tau clearance